Pfizer's last bid to reverse Lilly's CDK4/6 early-stage takeover fails, as a second Ibrance study falters
Eli Lilly staged a coup over the summer, showing their CDK4/6 drug Verzenio could help prevent recurrence in early-stage breast cancer patients just 3 …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
